Developing new tools to design shorter antibiotic treatments for tuberculosis
BEYOND BURDEN: NEW TOOLS FOR TUBERCULOSIS ANTIBIOTICREGIMEN DESIGN
This study is looking for better ways to treat tuberculosis (TB) by finding out how different antibiotics can work faster and more effectively, which could help patients get better in less time.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project ID | NIH-10816584 on NIH RePORTER |
What this research studies
This research aims to address the global tuberculosis (TB) epidemic by creating new methods to shorten the treatment duration required for curing TB. It focuses on understanding how different antibiotics affect the bacteria responsible for TB, particularly how they penetrate lung lesions and target drug-tolerant populations. By evaluating the impact of these drugs on bacterial processes, the research seeks to identify more effective treatment regimens. Patients may benefit from shorter and more effective TB treatments as a result of this innovative approach.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with tuberculosis who require antibiotic treatment.
Not a fit: Patients with drug-resistant tuberculosis or those who have already completed TB treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to significantly shorter treatment times for tuberculosis patients, improving their quality of life and treatment adherence.
How similar studies have performed: Previous research has shown promise in developing new treatment strategies for tuberculosis, but this approach is innovative and aims to fill existing gaps in understanding drug efficacy.
Where this research is happening
Aurora, UNITED STATES
- University of Colorado Denver — Aurora, United States (Active)
Researchers
- Principal investigator: Voskuil, Martin Inua — University of Colorado Denver
- Study coordinator: Voskuil, Martin Inua
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.